Optiscan’s True Asset Value Exceeds $1 Billion

As you are all aware:

· The company currently has an experienced and competent board, who are across the medical technology and the commercial issues which they are addressing head on

· InVivage FDA approval will occur and coincides with the start of the significant evolution in artificial intelligence

· Favourable Oral cancer study results are due soon

· Favourable breast cancer surgical margin studies continue to expand

· Optiscan’s technology applies to all cancers

· Sales of ViewnVivo continue

· The earnings per share have increased

· The company has enough financial resources for more than 12 months

· Carl Zeiss’ neurosurgery platform continues to expand and exists solely because of Optiscan’s technology

· Carl Zeiss Meditech continues to collaborate with Optiscan

· The company’s Board have identified future risks and put in processes to mitigate risks

· There is a future option to raise funds without diluting share equity (non-dilutive funding), only if required

· The top 20 shareholders hold over 60+% of the issued shares

· The CEO has share options that are exercisable when the share price reaches $1.00 and $1.50 and $2.00

· A large number of Optiscan employees hold shares in the company

· Optiscan’s technology is the best in the world, confirmed by hundreds of medical journal reviews

· Covid-19 impacted Optiscan’s timetable but the company is now back on track

However, all are not aware that Optiscan’s technology is a consequence of 25+ years of research and development.

Between $500 million to $1 Billion has been spent by Optiscan to achieve what we have today.

The market for Optiscan’s technology over the next five years is over $10 Billion.

The value of the Optiscan’s intellectual property is enormous.

Clearly, Optiscan’s True Value Exceeds $1 Billion.